title: [Metronomic chemotherapy combined with dendritic cell vaccine  inhibits VEGF secretion].
abstract: OBJECTIVE
  The survival rate of lung cancer is low, thus new methods for treating this form of cancer must be explored. This study applies immune therapy with metronomic chemotherapy to observe the effect of combined therapy on suppressing tumor.
  
  
  METHODS
  Mice were inoculated with Lewis lung carcinoma cells. Different treatments, namely, saline, metronomic chemotherapy, dendritic cell (DC) vaccine, and metronomic chemotherapy with DC vaccine were administered to corresponding mice groups. Basic fibroblast growth factor and vascular endothelial growth factor (VEGF) were detected via microdialysis and Luminex.
  
  
  RESULTS
  The median survival time of mice in the metronomic chemotherapy with DC vaccine group was (27.6±3.2) days, whereas that in the saline group was (13.5±2.7) days (P=0.008), that in the DC) vaccine group was (13.1±2.3) days (P=0.01), and that in the metronomic chemotherapy group was (11.8±3.0) days (P=0.01). The mice in the metronomic chemotherapy with DC vaccine group exhibited longer survival time than the mice in the other groups. This result could be related to the downregulation of VEGF secretion in the tumor-bearing mice groups within 48 h to 72 h.
  
  
  CONCLUSIONS
  VEGF secretion could be downregulated in tumor-bearing mice by administering metronomic chemotherapy with DC vaccine.
authors.affiliation: Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhou
authors.forename: Huimin
authors.initials: H
authors.lastname: Wang
authors.forename: Hua
authors.initials: H
authors.lastname: Zhong
mesh_terms: D059250:Administration, Metronomic; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism / Q000401:mortality; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
chemical_list: D019496:Cancer Vaccines; D042461:Vascular Endothelial Growth Factor A
references.citation: Eur J Immunol. 2010 Aug;40(8):2123-30
references.pmid: 20853498
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Lancet Oncol. 2011 Jan;12(1):15
references.pmid: 21249722
references.citation: J Intern Med. 2011 Jan;269(1):64-73
references.pmid: 21158979
references.citation: Nat Rev Cancer. 2004 Jun;4(6):423-36
references.pmid: 15170445
references.citation: Int J Cancer. 2009 Jun 15;124(12):2989-96
references.pmid: 19319982
references.citation: Nat Rev Clin Oncol. 2010 Aug;7(8):455-65
references.pmid: 20531380
references.citation: Eur J Immunol. 2011 Jan;41(1):18-25
references.pmid: 21182072